首页 | 官方网站   微博 | 高级检索  
     


Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors
Authors:Aung Naing MD  Alain P Algazi MD  Gerald S Falchook MD  Benjamin C Creelan MD  John Powderly MD  Seth Rosen MD  Minal Barve MD  Niharika B Mettu MD  PhD  Pierre L Triozzi MD  John Hamm MD  Gongfu Zhou PhD  Chris Walker BS  Zhiwan Dong PhD    Manish R Patel MD
Affiliation:1. MD Anderson Cancer Center, University of Texas, Houston, Texas, USA;2. University of California San Francisco, San Francisco, California, USA;3. Sarah Cannon Research Institute at HealthONE, Denver, Colorado, USA;4. Moffit Cancer Center, Tampa, Florida, USA;5. Carolina BioOncology Institute, Huntersville, North Carolina, USA;6. Hematology Oncology Associates of the Treasure Coast, Port St Lucie, Florida, USA;7. Mary Crowley Cancer Research, Dallas, Texas, USA;8. Duke University Medical Center, Durham, North Carolina, USA;9. Wake Forest University, Winston-Salem, North Carolina, USA;10. Norton Cancer Institute, Louisville, Kentucky, USA;11. Incyte Corporation, Wilmington, Delaware, USA;12. Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida, USA
Abstract:
Keywords:durvalumab  epacadostat  kynurenine  neoplasms  PD-1
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号